|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Medtronic, Inc. (MDT) And NeuroPace, Inc. Cross License Patents For Treating Neurological Disorders; Agreement Fosters Advancements In Detection And Treatment Of Epilepsy
10/19/2005 5:09:05 PM
MINNEAPOLIS--(BUSINESS WIRE)--Aug. 4, 2005--Medtronic, Inc. (NYSE:MDT), today announced that it has entered into a patent cross-licensing agreement with NeuroPace, Inc., a privately held medical device company specializing in the detection, treatment and monitoring of epilepsy and other neurological disorders via responsive brain stimulation. Under the terms of the royalty-bearing, non-exclusive agreement, the two companies cross-licensed patents and patent applications of neurological technology related to direct electrical stimulation or monitoring of the brain. Specific terms of the agreement were not disclosed.
"The agreement allows Medtronic to further develop and expand its innovative portfolio of therapies for patients suffering from neurological disorders, with the most immediate application in sensing and treating refractory epilepsy," said Jon Tremmel, president, Medtronic Neurological. "Epilepsy remains a devastating disorder for patients who don't respond to medications. A closed-loop system that can detect and prevent seizures could greatly change how physicians and patients manage this condition."
|
|
|
|
|
|
|
|
|
|
|